Table 3.
Low dose group n (%) | High dose group n (%) | Absolute standardized differences | |
---|---|---|---|
119,376 (100.0) | 119,376 (100.0) | ||
Age, mean (SD)a | 64.5 (11.2) | 64.6 (11.1) | 0.012 |
Male sexb | 59,870 (50.2) | 60,368 (50.6) | 0.008 |
At least 5 medical outpatient visitsb,d | 69,706 (58.4) | 67,866 (56.9) | 0.031 |
At least 1 hospitalizationc | 28,176 (23.6) | 29,679 (24.9) | 0.029 |
Myocardial infarctionc | 7427 (6.2) | 8605 (7.2) | 0.039 |
Stroke | 3515 (2.9) | 3961 (3.3) | 0.021 |
Hypertension | 49,608 (41.6) | 49,833 (41.7) | 0.004 |
Dyslipidemia | 38,734 (32.5) | 38,328 (32.1) | 0.007 |
Peripheral vascular disease | 2248 (1.9) | 2742 (2.3) | 0.029 |
Congestive heart failure | 4977 (4.2) | 5804 (4.9) | 0.033 |
Coronary artery bypass graft | 1550 (1.3) | 1717 (1.4) | 0.012 |
Percutaneous coronary interventionc | 4541 (3.8) | 5324 (4.5) | 0.033 |
Dispensation of loop diureticsd | 6852 (5.7) | 7604 (6.4) | 0.026 |
Dispensation of calcium blockersd | 26,961 (22.6) | 27,501 (23.0) | 0.011 |
Dispensation of beta-blockersb,d | 32,994 (27.6) | 37,067 (31.1) | 0.075 |
Dispensation of angiotensin receptor blockersb,d | 20,479 (17.2) | 21,877 (18.3) | 0.031 |
Dispensation of angiotensin converting enzyme inhibitorsb,d | 24,286 (20.3) | 26,996 (22.6) | 0.055 |
At least 5 different drugs dispensedd | 68,169 (57.1) | 69,442 (58.2) | 0.022 |
Comorbidity status, drug dispensations, and medical utilization rates were assessed in the year prior to the cohort entry date. Absolute standardized differences are defined as the between group difference as a proportion of the pooled standard deviation of the two groups
aAt the cohort entry date
bIdentifies baseline characteristics which had 0.10< ASDD ≤0.20 within the unmatched populations [7]
cIdentifies baseline characteristics which had ASDD >0.20 within the unmatched populations [7]
dIdentifies covariates which were hidden to the hdPS algorithm within the hdPS hidden info model